Skip to content
RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
Rockwood Research
…

CRSP

CRISPR Therapeutics AG

Biological Products, (No Diagnostic Substances) · SIC 2836CIK 1674416Held by 3 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:XLINKEDINEMAIL
Revenue FY2025
$<0.01B
Net Income FY2025
$(0.58B)
EPS (Basic, as reported)
$-6.47
Net Margin FY2025
-16569.8%
ROE FY2025
-30.3%
Total Equity
$1.92B
Shares Out
97M
Business description

CRISPR Therapeutics AG — Biological Products, (No Diagnostic Substances). Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2014–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions
i
default rows · click any row to chart itRevenue: 5 → 4 -2.4% CAGR
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue541329019151371374
Research & development(42)(70)(114)(179)(267)(439)(462)(387)(321)(285)
General & administrative(31)(36)(48)(63)(88)(103)(102)(76)(73)(74)
Total operating expenses(73)(106)(162)(243)(355)(541)(674)(594)(504)(668)
Operating income(68)(65)(159)47(354)374(673)(223)(467)(665)
Interest & investment income——————2376104—
Other income (expense), net45(2)(5)2166237210487
Pre-tax income(23)(67)(164)67(348)380(650)(151)(363)(578)
Income tax expense0(2)(1)0(1)(2)0(3)(4)(4)
Net income(23)(68)(165)67(349)378(650)(154)(366)(582)
EPS — basic—($1.71)($3.44)$1.23($5.29)$4.97($8.36)($1.94)($4.34)($6.47)
EPS — diluted—($1.71)($3.44)$1.17($5.29)$4.70($8.36)($1.94)($4.34)($6.47)
Shares outstanding — basic (M)—404854667678798490
Shares outstanding — diluted (M)—404857668078798490

Showing the latest 10 of 12 fiscal years.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.